Company news
ViaDerma, Inc. news in 2017
ViaDerma, Inc.'s news releases, calls and decks from 2017, newest first.
ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018
December 7, 2017
ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products
November 21, 2017
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx
October 19, 2017
ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada
September 8, 2017
ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan
August 18, 2017
ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product
July 27, 2017
ViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results
July 10, 2017
ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men
June 27, 2017
ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow
June 15, 2017
ViaDerma, Inc. Commences First Manufacturing Run and will Meet the 2nd Quarter Product Distribution Milestone
June 12, 2017
ViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies
May 15, 2017
ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company
May 3, 2017
ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks
April 19, 2017
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
March 20, 2017
ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch
March 8, 2017
ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries
February 15, 2017
Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes
February 8, 2017
ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017, also Onychomycosis Clinical Studies Show Significant Results
February 3, 2017
ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling Viabecline Through Established Online Distribution Networks in 2017
January 11, 2017